BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld Asia
Home
» Regulatory actions for Sept. 21-27, 2021
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Regulatory actions for Sept. 21-27, 2021
Sep. 28, 2021
No Comments
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Advaccine, Akeso, Arcturus, Ascentage, Biogen, Biontech, Celltrion, Cytodyn, I-Mab, Innovent, Inovio, Junshi, Lion TCR, Luye, Novavax, Pfizer, Pharmamar, RDIF, Regeneron, Roche, Samsung Bioepis, Serum Life Sciences, Spero.
BioWorld Asia
Briefs
Regulatory actions